कोशिश गोल्ड - मुक्त
What Sebi’s trading rules revamp means
Mint Chennai
|January 13, 2026
The Securities and Exchange Board of India (Sebi) is proposing a major overhaul of trading rules, by simplifying longstanding regulations and shifting more day-to-day supervision to stock exchanges.
In a consultation paper released on Friday, Sebi proposed merging existing trading norms into a single consolidated circular. This would be done by revising the Master Circular for Stock Exchanges and Clearing Corporations (MSECC) and the Master Circular for Commodity Derivatives (MCCD). The aim is to streamline compliance, remove outdated provisions, and update norms that are more than a decade old. Mint explains what Sebi is proposing and why it matters for stock exchanges.
The consultation paper outlines a broad set of operational and regulatory changes. Among the most significant is a proposal to raise the minimum net-worth requirement for brokers offering the margin trading facility (MTF) from ₹3 crore to ₹5 crore—or higher, if exchanges choose to prescribe stricter norms.
The existing threshold was first introduced in 2004 and was last reviewed in 2022.
Other proposals include:
Aligning timelines for submission of net-worth statements and auditor certificates
Removing market-making provisions no longer in use
Bringing liquidity enhancement schemes (LES) under a single, principle-based framework
यह कहानी Mint Chennai के January 13, 2026 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
Mint Chennai से और कहानियाँ
Mint Chennai
Lenskart wants artificial intelligence to test your eyes
It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery
3 mins
January 13, 2026
Mint Chennai
More companies to take a hit as labour codes debut
Reworked gratuity and leave encashments spell additional expenses for India Inc
2 mins
January 13, 2026
Mint Chennai
HC lifts ban on Zydus cancer biosimilar till patent expiry
In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.
2 mins
January 13, 2026
Mint Chennai
Trump’s investigation of Powell is also a warning to the next Fed chair
The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.
3 mins
January 13, 2026
Mint Chennai
States flag Almont-Kid syrup as tests find contaminants
Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol
1 mins
January 13, 2026
Mint Chennai
India at 100: Our choices today will define the next two decades
India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path
4 mins
January 13, 2026
Mint Chennai
Now, inheritance works without probate—but why it still matters
Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases
6 mins
January 13, 2026
Mint Chennai
Why VCs have a new deep-tech playbook
where fundraising starts to drag,\" said Chand.
1 min
January 13, 2026
Mint Chennai
TCS, HCLTech deliver Q3 revenue surprise
clearer.
2 mins
January 13, 2026
Mint Chennai
US productivity is rising and it risks warping monetary policy
America's neutral rate ought to be going up but will the Fed listen?
3 mins
January 13, 2026
Listen
Translate
Change font size
